




The rise of e-cigarettes: Implications for health promotion  
Introduction 
In January 1964 the Smoking and Health Report of the Advisory Committee to the Surgeon General of 
the Public Health Service of the United States was released, identifying the adverse health effects of 
tobacco smoke.
1
 Since then the World Health Organisation (WHO) has attributed almost 6 million 
deaths per year to tobacco smoking, including those caused by second-hand smoke.
2
 For over four 
decades the health promotion and public health community have worked tirelessly to reduce smoking 
and curb the adverse health outcomes through actions such as smoke-free policies, tobacco taxes, 
advertising bans, social marketing campaigns, plain packaging and provision of cessation services, 
reducing adult daily smoking rates in Australia from 35% in 1983 to 13% in 2013.
3
  However, the 
situation has now changed with the emergence of e-cigarettes (ECs).  The debate is on as to whether 
this new nicotine delivery device has the potential to exacerbate nicotine addictions, or play a part in 
harm reduction and smoking cessation? 
 
ECs products 
ECs in their current form were invented in 2003, and entered the US market in 2007,
4
 and since then 
have experienced a rapid growth. ECs are nicotine delivery devices that use batteries to heat up liquid 
(EC juice), typically containing propylene gel and nicotine. 
5
 By inhaling, the user activates the circuit 
within the device that heats the liquid and turns it into a vapour that they breathe in. The EC delivery 
devices can have the appearance of a fountain pen, lipsticks or even an USB, making them much like a 
fashion accessory, novel and attractive to purchasers. The EC-juice or liquid that is used in the 
delivery device comes in 7700 different flavours, such as chocolate, gummy bears and cola, which 
may particularly appeal to the young.
6
 The EC-juice in vials vary in the content of non-controlled 
nicotine concentrations, in a range of solution volumes and different carrier compounds (usually 
propylene glycol).
7
 This often results in the nicotine levels in the EC vapour not correlating with the 
nicotine concentration listed on the vial packaging,
8




EC use is growing exponentially worldwide. In the United States (US) and United Kingdom (UK) 
between 2010 and 2012, the use of ECs doubled from 3.3% to 6.2% (US) and 2.7% to 6.7% in the 
UK,
9
 while the percentage of Australians who had tried ECs increased from 2% in 2010 to 16.8% in 
2013.
10
 The National Drug Strategy Household Survey ( 2013)
3
 showed that close to 1 in 7 smokers 
aged 14 or older have used ECs in the last 12 months, with those aged 18-24 more likely users 
This is the accepted version of an article published as: Jancey, J. and Binns, C. and Smith, J. and Maycock, B. and Howat, P. 2015. Editorial. The  
rise of e-cigarettes: Implications for health promotion. Health Promotion Journal of Australia. 26 (2): pp. 79-82. doi: http://doi.org/10.1071/HEv26n2_ED
2 
 
(27%) than older smokers aged 60-69 years (7.2%). Australian data on daily EC use is not available 
but is urgently needed to better understand the issue. 
 
Some data suggests that ‘never smokers’ are less likely than ‘former or current smokers’ to have tried 
ECs. In 2011-12 ‘ever users’ of ECs among US high school students more than doubled and in 2012, 
one in five middle school children who identified as ‘ever users’ of ECs reported never smoking 
regular cigarettes.
11
 Beyond this, a recent study in Ireland showed 5% of smokers began using ECs 
before they switching to regular cigarettes.
12
  Critics have suggested that most of the research that has 
been undertaken to date is cross sectional and this methodology may not yet have captured the 




Safety of ECs 
Although ECs do not deliver tar or carbon monoxide,
13
 they do expose users and those nearby to 
particulate matter, organic compounds and solvents.
14
 Many of these chemical substances and 
particulates are toxic, carcinogenic and cause respiratory and heart distress. 
15
 In addition, ECs have   




However, due to the relatively short time ECs have been available there is little data relating to 
t hei r  long- term health effects.  A recent systematic review reported that common 
carcinogens are lower in ECs compared to tobacco products (e.g. nitrosamines). However, 
the researchers concluded that due to the inconsistencies in evidence and lack of long term 





from his systematic review of chemical compositions of EC -juice that the level and type of 
exposure to users and other people in proximity is difficult to establish.  This is due to the 
range of components in the juices and the differences in delivery performance of EC 
devices.  Although ECs appear to deliver lower levels of some chemicals compared to 
regular cigarette, there is no evidence that they are a healthier alternative.
18
  Drummond warned that 
the perception of  ECs as a harm reduction tool without adequate evidence can be likened to the 




Smoking cessation or marketing tool 
The evidence around ECs role in smoking cessation is inconclusive with experts stating ‘the goal of 
ECs makers is not cessation of tobacco use but ‘dual use.’ 
19
 The Cochrane review
20
 examining ECs 
as a cessation tool showed that they may have similar efficacy to nicotine patches. However, the 
findings were inconclusive due to the small amount of evidence available (i.e. only two randomised 




Promotion of ECs 
ECs have increased in popularity and have been enthusiastically promoted as a smoking cessation aid 
and healthy alternative to regular cigarettes, even though these claims are unsubstantiated.
21
 Major 
tobacco companies are purchasing or developing EC products,
7
 and using websites and twitter to reach 
large audiences at a relatively cheap cost.
22
 At the 2014 Electronic Cigarette Education Summit, a 







 reviewed 59 websites that sold ECs and found claims such as, ECs were a 
healthier product (95%), cheaper and cleaner than regular cigarettes (93%), can be smoked anywhere 
(88%), used to get around smoke-free polices (71%), no side-stream smoke just water vapour (76%) 
and could act as a worthwhile cessation aid (64%). These marketing messages are also repeated via 
social media such as Facebook and twitter, where EC companies have a strong presence. This is the 
perfect place to reach new markets as Twitter users are mainly from younger age groups.
24
  In addition, 
some ECs are promoted as a lifestyle choice, associated with stylish accessories and celebrities. They 
have essentially been promoted by Katherine Heigl on the David Letterman Show, Johnny Depp’s 




Regulation of sales of ECs 
Many countries have banned over the counter sales of ECs including Australia, Canada, Mexico, and 
Brazil. As a consequence, ECs are sold largely via the internet, making their sales difficult to regulate 
but still accessible, particularly to the young, as this is their preferred purchasing medium.
26
 In early 
2014 there was an estimated 466 brands of ECs available on line, with up to 50% of sales occurring on 
the internet.
27
 The exact amount of sales of ECs is difficult to determine, although two US companies 




Australian laws covering ECs are complex, vary between states and are difficult to enforce.
10
  
Currently, tobacco control laws do not apply to ECs, rather poisons control legislation in all Australian 
jurisdictions prevents the sale, possession or use of non-therapeutic nicotine without a licence. A few 
states (e.g. Western Australia, South Australia and Queensland) have also banned delivery devices that 








In Australia the regulation for the importation of ECs by purchasers is detailed on the Customs Website 
(http://www.customs.gov.au/faq/AlcoholCigTobacco2.asp#Q365), with EC regulations relating to EC 
importation appearing quite convoluted. The information on the site states that in Australia liquid 
nicotine is listed as a ‘Schedule 7 Poison’ under the Standard for the Uniform Scheduling of Medicines 
and Poisons (SUSMP) but it is not a prohibited import. They may be subject to control under the 
Therapeutic Goods (TGA) Act 1989 if the packaging makes a claim about any form of therapeutic 
benefit but this is not usually included on the packaging. If no therapeutic claim is made, or the TGA 
determines that no action is warranted, the goods are released to the purchaser. These products are not 
deemed to be tobacco or tobacco products, and therefore are not subject to duty or GST if the customs 
value is at or below the low value goods threshold of A$1,000.
29
 This makes the purchase of ECs via 
the internet, appealing and relatively easy. 
 
Restricting use of ECs 
The WHO has called for greater restrictions on the use, sale and promotion of ECs as there is limited 
evidence on their safety and their role to help smokers to quit.
30
  The Cancer Council, Australia and 
National Heart Foundation support a ban on the sale of nicotine delivery devices.
31
 A recent position 
statement by the NHMRC reported that there is insufficient evidence that ECs are a safe alternative to 
tobacco and supports research to assess their health impact
32
  and the Australian Medical Association 




A number of cities in the US have moved to address the use of ECs. The city of Boston has applied 
workplace EC bans, with New York and Los Angeles ready to introduce legislation that will prohibit 
their use in public places. 
19
 In Australia, the University of South Australia lead the charge, 
announcing on May 31 2014 
34
 that they would ban the use of ECs on campus. This has been followed 
by the Australian National University whose ban on ECs became effective on May 31 2015.
35
 
Queensland is the first Australian state to subject ECs to the same laws for people who use regular 




Implications for Health Promotion 
The health promotion community is in an unenviable situation with limited data on which to base their 
position on ECs. Hence, there is no firm consensus.  Some see ECs as a safe form of nicotine delivery 
in comparison to regular tobacco, as well as a tobacco cessation device and harm reduction strategy, 
even though they have not been adequately tested, standardised or regulated. 
37
 Others see it as a 
coercive entry point or ‘gateway’ for the young to a life of smoking and ill health, and an ideal 
opportunity for the re-normalising and re-glamourizing of societal smoking.
38
  However, we should 
remember that nicotine replacement and cessation programs played only a minor role in the decline in 
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regular smoking prevalence. The main influences were due to a comprehensive health promotion 
approach of that restricted access and opportunities to smoke.  
It appears that we will have to remain wary of the tobacco industry as their recent actions mirror a 
history of deviousness.
1
  This was illustrated in New South Wales recently, where the state government 
delayed laws to restrict minors from obtaining ECs after Members of Parliament were approached by 
lobbyists representing multinational tobacco companies.
39
 This ongoing distrust of the tobacco industry 
provides good reason for their exclusion from any policy development related to ECs.   
From the limited evidence we have to date on ECs, it is apparent that a cautious approach is warranted 
with a case that supports strict regulation until rigorous research is conducted. The same rigor that is 
applied to new therapeutic products needs to be applied to ECs. Randomised controlled trials are 
needed to compare ECs to other nicotine replacement therapies and research studies should be designed 
to assess long-term health outcomes of EC use. 
Legislation should be considered that restricts EC sales to adults over 18 years who are attempting to 
reduce or quit smoking. This could be an interim measure based on the assumption that research may 
eventually indicate relative safety as well as effectiveness of ECs as a cessation agent. Legislation 
should also consider: standardisation of EC products; a requirement that all EC brands list their juice 
ingredients and nicotine contents; restrictions on the flavours to make them less appealing to children; 
making juice containers childproof; non-glamorised common generic packaging; careful controls on the 
marketing of ECs; restricting sales avenues, banning of online sales/purchases; and banning of 
unsubstantiated claims regarding quitting and health benefits. 
In conclusion, there are still too many unknowns about the likely consequences of EC use to allow it 
uncontrolled availability and we therefore need to consider the ‘precautionary principle’ when dealing 
with this issue. Short-term research should be able to identify the relative safety of the product and its 
benefits as a cessation agent. However, long-term research may be necessary to identify its potential 
impact on smoking behaviours of children, youth and adults, including rates of uptake. As ECs are a 
smoking related product with close connections to the tobacco industry, ‘caution is the better part of 
valour’! We do not want decades of health promotion practice and public health policy that has 
successfully reduced smoking prevalence to be undone. 
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